New treatment guidance has been developed to help doctors tackle uveitis—one of the leading causes of vision loss. The new clinical guidance, by a team at the University of Bristol, aims to help ...

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

Local therapy can work as well as systemic therapy in uveitis management, with shorter-acting steroid agents working better for acute disease and longer-acting agents working better for recurring ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Glucocorticoids should be bridging therapies in the treatment of juvenile idiopathic arthritis–associated uveitis (JIAU) and idiopathic chronic anterior uveitis (CAU), according to recently released ...

VT-1908 eyedrop achieves the desired concentration in the anterior chamber of the eye and significantly reduces uveitis score in preclinical models (P<0.001) CAMBRIDGE, Mass., September 17, ...